Ionis Pharmaceuticals wins a regulatory milestone as the U.S. FDA approves its therapy for a rare brain white-matter disorder, marking the first treatment for this genetic disease. The approval could unlock near-term upside and broaden Ionis' platform value, with commercialization and payer dynamics likely driving shares. Uptake, pricing, and potential competitive dynamics remain key watching points.
Ionis surged as it inked a global licensing deal with Recordati for Zilganersen outside the U.S., while Tryngolza received FDA clearance with a July U.S. launch potential. The combination of near-term regulatory milestones and international commercialization options could strengthen Ionis’ revenue trajectory and cash flow into 2028, complementing its U.S. neurology efforts.
Ionis Pharmaceuticals has revised the wholesale acquisition cost for its drug Tryngolza to $40,000, effective April 1, in anticipation of FDA approval for sHTG by June 30. This strategic pricing adjustment may enhance formulary inclusion and drive significant revenue potential, with estimates reaching $2.6 billion based on earlier projections.
Ionis Pharmaceuticals reported a Q4 adjusted loss of $1.15, surpassing Wall Street's estimate of $1.32. This better-than-expected performance may positively influence investor sentiment, though focus remains on future growth prospects and pipeline developments.
Olezarsen reduces fasting triglyceride levels by up to 72%. 85% reduction in acute pancreatitis events observed with olezarsen. 86% of patients achieved triglyceride levels below 500 mg/dL. IONS plans to submit supplemental FDA application by year-end. Shares retreated 5.21% at publication time.
Zilganersen shows positive results for treating Alexander disease in pivotal study. Statistically significant improvement in gait speed observed after 61 weeks. First investigational drug to demonstrate disease-modifying effects in AxD. Ionis to submit a new drug application to the FDA in Q1 2026. Share price rose 4.88% during premarket following positive study results.
